Pioneering Healthcare: Evexia's Strategic Acquisition in Regenerative Medicine

Evexia Lifecare Limited has signed a significant agreement to acquire a 65% stake in Diponed Bio Private Limited, a leader in regenerative medicine. This strategic acquisition aims to expand Evexia's footprint in biotechnology, fostering innovation and growth in cell-based therapies and tissue engineering.

In a landmark move, Evexia Lifecare Limited has entered into an agreement to acquire a formidable 65% stake in Diponed Bio Private Limited. This strategic venture represents Evexia's targeted expansion into regenerative medicine and biotechnology.

Evexia’s acquisition includes 18,600 fresh equity shares valued at Rs. 10 each, marking its commitment to hold a majority stake in Diponed Bio. This investment underscores Evexia's broader business strategy to leverage emerging market opportunities in healthcare and biotechnology.

With a funding infusion of INR 200 million programmed for Diponed Bio, Evexia aims to bolster research capabilities and innovation. This alliance is set to accelerate developments in stem cell therapies and gene editing, redefining future medical treatments.

(With inputs from agencies.)